Events

WCLC 2019

WCLC 2019

WCLC 2019

7-10 September 2019

Barcelona, Spain

Booth #400

 

 

ATTEND OUR EDUCATIONAL LUNG CANCER WORKSHOP

 

Please join our educational lung cancer workshop: Clinical Value of Diagnostic Agility in Managing Patients with Lung Cancer

 

Saturday, 7 September, 07:30 - 11:30 | Room Seoul (2007)

 

Please join a distinguished panel of experts as they explore the patient journey through lung cancer diagnosis and treatment decisions. In this workshop, they will examine the value of both current and cutting-edge new technologies in assessing lung cancer biomarkers such as ALK, EGFR, ROS1 and PD-L1-and their roles in a multidisciplinary approach to managing patient care. Case reviews of biomarker testing scenarios and an interactive session will illustrate how clinical decision support can better enable and inform timely, accurate treatment for patients.

 

SEE OUR POSTER PRESENTATIONS

 

Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology
 
Sunday, 8 September, 09:45 - 18:00 | Exhibit Hall | Poster 2864

 

To assess the potential impact of clonal hematopoiesis (CH) in disease monitoring, we evaluated monitoring algorithms by targeted sequencing with and without matched peripheral blood mononuclear cells (PBMC). Our results suggest that for disease monitoring applications in a non-MRD setting, measuring multiple variants instead of a single variant further enables robust classifiers that can moderate the impact of variants, if any, from CH.

 
Early Assessment of Therapy Response in Non-small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis

 

Monday, 9 September, 10:15 - 18:15 | Exhibit Hall | Poster 2795

 

Using a ctDNA-based monitoring algorithm, we evaluated the association between survival and ctDNA levels in the first available post-treatment plasma sample in 83 stage IV lung adenocarcinoma 22 late stage lung squamous cell carcinoma that underwent chemo or chemoradiation therapies. We found that early response can be assessed by ctDNA level to predict treatment effect.

 

VISIT OUR BOOTH

 

Come visit booth #400 to hear more about our Diagnostics Oncology Solutions

AVENIO NGS Assays for Clinical Research*

AVENIO NGS Assays

Liquid biopsy and tumor tissue assays for comprehensive genomic profiling, surveillance & monitoring.  AVENIO NGS assays are for Research Use Only. Not for Use in Diagnostic Procedures.

 

*Research Use Only. Not for use in diagnostic procedures.

Learn more

cobas® EGFR Mutation Test v2

cobas® EGFR Mutation Test v2

The only FDA-approved diagnostic test for NSCLC using liquid biopsy.

Companion diagnostic for Tarceva® (erlotinib), IRESSA® (gefitinib) & TAGRISSO® (osimertinib)

NAVIFY® Mutation Profiler**

NAVIFY® Mutation Profiler

A clinical NGS reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations, empowering clinicians to deliver more personalized healthcare.

**Not yet commercially available in the US

Learn more

NAVIFY® Tumor Board

NAVIFY® Tumor Board

Developed as a result of the collaboration between Roche and GE Healthcare, NAVIFY Tumor Board is a cloud-based workflow product that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology care teams to review, align and decide on the optimal treatment for the patient.

 

Learn more

Digital Pathology solution

Digital Pathology solution

The Roche Digital Pathology solution combines innovative hardware, software and VENTANA Companion Algorithm image analysis software, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience.A high-speed slide scanner for digital pathology. Its unique, tray-based design enables no-touch slide processing for reduced workflow errors and produces excellent image quality and reliability.

Learn more

 

AVENIO, COBAS, NAVIFY and VENTANA are trademarks of Roche. All other product names and trademarks are the property of their respective owners.